FDA approves generic Strattera
On May 30, the U.S. Food and Drug Administration approved the first generic versions of Strattera (atomoxetine) to treat attention‐deficit hyperactivity disorder (ADHD) in pediatric and adult patients.
Source: The Brown University Child and Adolescent Psychopharmacology Update - Category: Psychiatry Tags: From the FDA Source Type: research
More News: ADHD | Children | Food and Drug Administration (FDA) | Hyperactivity | Pediatrics | Psychiatry | Strattera